Bernard Harris - US Physicalrapy Independent Director
| USPH Stock | USD 105.20 1.56 1.51% |
Director
Dr. Bernard A. Harris, Jr. is an Independent Director of the Company. He joined our Board on August 23, 2005. Since 2001, Dr. Harris was President and Chief Executive Officer of Vesalius Ventures, a VC firm that invests in early stage medical informatics and technology. Since 2009, he has served as an independent director of Salient Funds, an asset management firm. From 2006 to 2011, Dr. Harris has served as a Class III director of Sterling Bancshares, Inc., a bank holding company. From 1996 to 2001, he served as Chief Medical Officer and Vice President for Space Hab, an aerospace company since 2005.
| Age | 64 |
| Tenure | 19 years |
| Address | 1300 West Sam Houston Parkway South, Houston, TX, United States, 77042 |
| Phone | 713 297 7000 |
| Web | https://www.usph.com |
US Physicalrapy Management Efficiency
The company has return on total asset (ROA) of 0.0469 % which means that it generated a profit of $0.0469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0655 %, meaning that it created $0.0655 on every $100 dollars invested by stockholders. US Physicalrapy's management efficiency ratios could be used to measure how well US Physicalrapy manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.03. The current Return On Capital Employed is estimated to decrease to 0.07. As of now, US Physicalrapy's Total Current Assets are increasing as compared to previous years. The US Physicalrapy's current Non Currrent Assets Other is estimated to increase to about 165.9 K, while Net Tangible Assets are forecasted to increase to (245.4 M).Management Performance
| Return On Equity | 0.0655 | ||||
| Return On Asset | 0.0469 |
US Physicalrapy Leadership Team
Elected by the shareholders, the US Physicalrapy's board of directors comprises two types of representatives: US Physicalrapy inside directors who are chosen from within the company, and outside directors, selected externally and held independent of USPH. The board's role is to monitor US Physicalrapy's management team and ensure that shareholders' interests are well served. US Physicalrapy's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, US Physicalrapy's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chadd Pence, Senior Systems | ||
| PT MBA, Chief West | ||
| Jason Anderson, Vice Resources | ||
| Glenn McDowell, Chief Operating Officer - West | ||
| Jon Bates, VP Controller | ||
| Christopher Reading, President, Chief Executive Officer, Director | ||
| Mark Brookner, Independent Director | ||
| Richard Binstein, Executive Vice President General Counsel, Secretary | ||
| Kathleen Gilmartin, Independent Director | ||
| Edward Kuntz, Independent Chairman of the Board | ||
| Anne Motsenbocker, Director | ||
| Clayton Trier, Independent Director | ||
| Eric Williams, Co-Chief Operating Officer - West | ||
| Graham Reeve, Chief Operating Officer - East | ||
| Bernard Harris, Independent Director | ||
| Reginald Swanson, Director | ||
| Carey Hendrickson, Chief Financial Officer | ||
| ATC PT, VP Officer | ||
| Harry Chapman, Independent Director | ||
| Jake Martinez, Senior Accounting |
USPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is US Physicalrapy a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0655 | ||||
| Return On Asset | 0.0469 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 1.86 B | ||||
| Shares Outstanding | 15.07 M | ||||
| Shares Owned By Insiders | 1.65 % | ||||
| Shares Owned By Institutions | 98.35 % | ||||
| Number Of Shares Shorted | 619.71 K | ||||
| Price To Earning | 34.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for USPH Stock analysis
When running US Physicalrapy's price analysis, check to measure US Physicalrapy's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy US Physicalrapy is operating at the current time. Most of US Physicalrapy's value examination focuses on studying past and present price action to predict the probability of US Physicalrapy's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move US Physicalrapy's price. Additionally, you may evaluate how the addition of US Physicalrapy to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is US Physicalrapy's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 1.72 | Earnings Share 1.28 | Revenue Per Share 42.193 | Quarterly Revenue Growth 0.096 |
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.